Our researchers have developed a novel drug combination of FDA-approved compounds that achieve significant therapeutic effects in the treatment of ARHL. These compounds include aldosterone, ammonium chloride, and an anti-inflammatory compound. The initial evidence from in vitro experiments, and in vivo studies of aging mice supports the effectiveness of this new drug formulation. This new treatment should preserve hearing while modulating the degeneration of spiral ganglion in aging cochlea. This technology may be an effective new treatment for ARHL.
The New Drug Combination Upregulates the Expression and Activity of NKCC1 Ion Channels to Improve the Flow of Potassium Ions in the Cochlea to Help Hearing